Clinical Efficacy of Decitabine/Azacitidine in Combination with HAG in the Treatment of Elderly Patients with Acute Myeloid Leukemia

Abstract

This study was conducted to investigate the clinical effect of combining decitabine/azacitidine with HAG in the treatment of single elderly patients with acute myeloid leukemia. Patients in Shaanxi Provincial People’s Hospital were selected for this study from January 2020 to January 2022, and all of the patients were elderly patients with acute myeloid leukemia. Around 23 patients were selected for this study, subsequently the patients were divided into two groups; Group A contained 11 patients and was given decitabine in combination with HAG; and Group B contained 12 patients, and was given azacitidine in combination with HAG. This study showed that the treatment effective rates of patients in both groups were 90.91% and 58.33%, respectively, with a small difference (P>0.05) in the data comparison. The incidence of adverse reactions in the two groups was 63.64% and 16.67%, respectively, with the incidence in group B is significantly (P<0.05) lower compared with group A. Meanwhile, compared with group B, patients in group A had a significantly (p<0.05) shorter mean time to WBC normalization, higher HB and PLT levels, lower WBC levels were lower, all the survival duration times were longer, and subpopulation indicators of peripheral blood T lymphocytes were more in line with normal values. In summary, this study demonstrated that the combination of azacitidine and HAG therapies for the treatment of elderly patients with acute myeloid leukemia is more effective, furthermore can reduce significantly the incidence of adverse treatment effects in patients.